Serum KL-6 improves prediction of progressive phenotype (PP) at one year independently of underlying interstitial lung disease (ILD): results from the VAMOS study.
F. Bonella (Essen, Germany), M. Vegas Sanchez (Madrid, Spain), D. Castillo Villegas (Barcelona, Spain), P. Millan-Billi (Barcelona, Spain), E. Gottstein (Essen, Germany), O. Sánchez Pernaute (Madrid, Spain), E. Bargagli (Siena, Italy), M. Molina Molina (Barcelona, Spain)
Source: International Congress 2022 – Hot topics in connective tissue disease-associated interstitial lung disease
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Bonella (Essen, Germany), M. Vegas Sanchez (Madrid, Spain), D. Castillo Villegas (Barcelona, Spain), P. Millan-Billi (Barcelona, Spain), E. Gottstein (Essen, Germany), O. Sánchez Pernaute (Madrid, Spain), E. Bargagli (Siena, Italy), M. Molina Molina (Barcelona, Spain). Serum KL-6 improves prediction of progressive phenotype (PP) at one year independently of underlying interstitial lung disease (ILD): results from the VAMOS study.. 1456
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|